Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218341 · ClinicalTrials.gov registry record · Phase 4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 4 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT07218341 is a Phase 4 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants.
The verdict
NCT07218341, a Phase 4 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Interventions
- DRUG Pirtobrutinib
- DRUG Idelalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2032-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218341
The ClinicalTrials.gov registry entry for NCT07218341 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pirtobrutinib is the first listed.
NCT07218341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07218341 about?
NCT07218341 is a clinical study titled "A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study interven...
What is the current status of trial NCT07218341?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2026-03-09. Estimated completion is 2032-12.
What interventions are being tested in trial NCT07218341?
The interventions under investigation include: Pirtobrutinib (DRUG), Idelalisib (DRUG).
Who is sponsoring clinical trial NCT07218341?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.